Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
The phase 3 trial showed that enzalutamide, when used as a monotherapy or in combination with leuprolide, resulted in superior metastasis-free survival rates for patients with high-risk biochemical recurrence of prostate cancer.
Oncology, Medical October 23rd 2023
Annals of Internal Medicine
ART-conceived singleton infants had an elevated risk for major genitourinary abnormalities. This risk remained unchanged even when accounting for parental infertility.
Endocrinology, Diabetes, Metabolism October 19th 2023
Renal & Urology News
Stay informed about the latest debates in prostate cancer treatment. Understand the implications of using docetaxel in high-risk localized cases.
Oncology, Medical October 17th 2023
MDLinx
This case serves as a stark reminder of the critical role accurate and timely record-keeping plays in patient care. How much do you trust your EMR?
All Specialties October 11th 2023
Cancer Therapy Advisor
Discover how local therapy options like radiotherapy and radical prostatectomy can significantly improve overall survival rates in cN1 prostate cancer patients.
Oncology, Medical October 9th 2023
Explore the complexities of prostate cancer treatment options through a detailed case study that weighs the benefits and risks of radical treatment versus active surveillance.